2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3815 Survival outcomes and biomarkers of disease modification: results from the phase 3 BOREAS study of navtemadlin (NVTM) in patients with JAK inhibitor (JAKi) relapsed or refractory (R/R) myelofibrosis (MF)

John O. Mascarenhas, MD, Maciej Kazmierczak2, Viola Maria Popov, MD3, Sanjay Mohan, MD, MSCI4, Zubeyde Nur Ozkurt, MD5, Jean-Jacques Kiladjian6, Andrew Charles Perkins, MBBS, PhD7, Prithviraj Bose, MD8, Hsin-An Hou9, Wojciech Homenda10, Monia Marchetti11, David M. Ross, MBBS, PhD12, Alessandro Maria Vannucchi13, Pankit Vachhani, MD14, Tracy Clevenger, PhD15, Cecile Krejsa, PhD16, Zhuying Huang17, Hope Qamoos, NP18, Jesse McGreivy19, Wayne Rothbaum, MS20, Srdan Verstovsek, MD21, Haifa Kathrin Al-Ali, MD22
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Poznan University of Medical Sciences, Ponzan, Poland
3 Colentina Clinical Hospital Bucharest, Hematology Department, Bucharest, Romania
4 The Vanderbilt Clinic, Nashville, Tennessee, United States
5 Gazi University, Faculty of Medicine, Department of Hematology, Ankara, Turkey
6 Hopital Saint-Louis, Paris, France
7 The Alfred Hospital and Monash University, Melbourne, Australia
8 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 National Taiwan University Hospital, Taipei, Taiwan
10 Institute of Health Sciences, Pomeranian University of Slupsk, Slupsk, Poland
11 Ospedale Cardinal Massaia, Asti, Italy
12 Royal Adelaide Hospital, Adelaide, South Australia, Australia
13 Center for Research and Innovation of Myeloproliferative Neoplasms University of Florence, Florence, Italy
14 The University of Alabama at Birmingham, Birmingham, Alabama, United States
15 Kartos Therapeutics, Inc., Redwood City, California, United States
16 Kartos Therapeutics, Inc., Redwood City, California, United States
17 Kartos Therapeutics, Inc., Redwood City, California, United States
18 Kartos Therapeutics, Inc., Redwood City, California, United States
19 Kartos Therapeutics, Inc., Redwood City, California, United States
20 Kartos Therapeutics, Inc., Redwood City, California, United States
21 Kartos Therapeutics, Inc., Redwood City, California, United States
22 Hematology Oncology, University Hospital of Halle, Halle, Germany

Introduction: Patients (pts) with JAKi-R/R MF have limited treatment options and poor outcomes, highlighting the need for novel and disease-modifying therapies. Navtemadlin (NVTM), a potent, selective mouse double minute 2 (MDM2) inhibitor, restores p53-mediated apoptosis in TP53 wild-type (TP53WT) MF cells. In clinical studies, NVTM demonstrated clinically meaningful improvements in spleen volume reduction (SVR) and total symptom score (TSS) with disease-modifying potential. Further, NVTM-induced reductions in driver gene variant allele frequency (VAF) and normalization of CD34+ MF cell counts were associated with prolonged progression-free survival (PFS) and overall survival (OS) (Vachhani 2023). In the Phase 3 BOREAS study (NCT03662126), NVTM improved SVR and TSS versus (vs) best available therapy (BAT) with clinical responses correlating with changes in biomarkers of disease modification (Mascarenhas 2024). This updated analysis of BOREAS evaluated long-term survival outcomes and associations with clinical responses and biomarkers of disease modification.

Methods: BOREAS is a global, open-label, Phase 3 study that enrolled adult TP53WT pts with primary or secondary MF who were R/R to JAKi treatment. JAKi-intolerant pts and suboptimal responders were excluded. Pts were randomized 2:1 to oral NVTM (240 mg once daily, days 1–7 of a 28-day cycle) or investigator-selected BAT. Crossover from BAT to NVTM was permitted following disease progression or at Week 24 (Wk24).

The primary endpoint was SVR ≥35% (SVR35) at Wk24 by blinded independent central review of MRI/CT imaging; TSS reduction ≥50% (TSS50) by MFSAF v4.0 at Wk24 was the key secondary endpoint. PFS and OS were prespecified secondary endpoints; SVR ≥25% (SVR25) was assessed post hoc. Exploratory endpoints included changes in driver mutation VAF and circulating CD34+ MF cell counts. Survival was assessed using Kaplan-Meier and Cox models in the intent-to-treat (ITT) population.

Results: 183 pts were randomized (NVTM, n=123; BAT, n=60) of 282 planned. Enrollment closed early following sponsor reprioritization to a pivotal study evaluating NVTM as add-on to ruxolitinib (POIESIS, NCT06479135). At data cutoff (July 23, 2026), 18 pts remained on NVTM treatment and 1 pt remained on BAT. Of 56 pts who received and discontinued BAT, 24 crossed over to NVTM. Mean (SD) treatment duration was 15.0 (14.26) months and 6.8 (6.99) months for NVTM and BAT, respectively.

NVTM demonstrated deepening and durable SVR in this poor-prognosis JAKi-R/R MF population. In the ITT population, SVR25/35 rates were 27%/15% for NVTM vs 10%/5% for BAT at Wk24, and 40%/28% vs 17%/13% at any time; median SVR25/35 duration was 66/49 vs 25/16 weeks. TSS50 rates at Wk24 were 24% for NVTM vs 12% for BAT. Median PFS was 38.9 vs 15.8 months (hazard ratio [HR]=0.685; P=0.23), and median OS was 44.7 vs 38.2 months (HR=0.768; P=0.30), despite interpretation being confounded by crossover.

In the NVTM arm, achievement of traditional measures of clinical response (SVR/TSS) were associated with improved survival outcomes. Longer PFS was observed among pts achieving SVR35 (HR=0.175; P<0.001), SVR25 (HR=0.12; P<0.001), and TSS50 (HR=0.575; P=0.13) vs nonresponders. Similar associations were observed for OS, including SVR35 (HR=0.546; P=0.083) and SVR25 (HR=0.517; P=0.038).

Biomarker analyses were also consistent with disease-modifying activity. A best overall reduction ≥50% in driver mutation VAF was achieved in 23% (24/104) of NVTM-treated pts vs 13% (6/48) with BAT, while normalization of circulating CD34+ MF cell counts (≤7 cells/µL) at Wk24 occurred in 33% (15/45) vs 5% (1/19), respectively. Among NVTM-treated pts, ≥50% VAF reduction was associated with longer PFS (HR=0.264; P=0.008) and a trend toward longer OS (HR=0.605; P=0.26). Similarly, normalization of CD34+ cell counts at Wk24 was associated with longer PFS (HR=0.301; P=0.054) and OS (HR=0.359; P=0.10).

Conclusions: In this updated analysis of BOREAS, NVTM demonstrated durable clinical activity, favorable survival trends versus BAT, and concordance between clinical responses, biomarkers of disease modification, and survival outcomes. Associations of SVR and TSS with PFS and OS reaffirm their clinical relevance, while reductions in driver mutation VAF and normalization of circulating CD34+ MF cell counts also aligned with improved survival outcomes, further supporting the disease-modifying potential of NVTM in TP53WT MF.

John O. Mascarenhas, MD: Italfarmaco Spa - Research Funding; Incyte - Research Funding; Geron - Research Funding; Dompe - Research Funding; DISC - Research Funding; Karyopharm - Research Funding; Novartis - Research Funding; PharmaEssentia - Research Funding; SOBI - Research Funding; Takeda - Research Funding; BMS - Research Funding; Kartos - Research Funding; Galecto - Research Funding; Kartos - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Italfarmaco Spa - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony); Damora - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); DISC - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Blueprint Medicines - Consultancy (Includes expert testimony); Keros - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Galecto - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony)